Siemens Healthineers Raises 2021 Forecast
Bloomberg · 07/30/2021 08:16
Siemens Healthineers Lifts Outlook on Sales of Covid Tests
Bloomberg · 07/30/2021 06:04
Merger Monday Returns as Siemens, Speedway Lead $40 Billion Haul · 08/03/2020 17:17
Siemens Arm��s $16.4 Billion Varian Deal Opens Path to DAX · 08/03/2020 07:09
This $16 Billion Cancer-Radiotherapy Deal Takes Two Leaps of Faith · 08/03/2020 07:01
Siemens Healthineers to Buy Varian in $16.4 Billion Deal · 08/03/2020 06:51
Beryl Capital Management’s Top Stock Picks
Insider Monkey · 12/31/2019 16:55
Analysts Estimate Corindus Vascular Robotics (CVRS) to Report a Decline in Earnings: What to Look Out for
Zacks · 10/29/2019 14:32
Corindus Vascular Robotics Reports Shareholders Have Approved Purchase By Siemens Healthcare
Benzinga · 10/25/2019 12:48
Corindus Highlights Will Showcase CorPath GRX System At Trancatheter Cardiovascular Therapeutics 2019 Conference On Fri., Sep. 27, 2019
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE:CVRS), a leading developer of precision vascular robotics, announced today it will showcase the capabilities of the
Benzinga · 09/18/2019 10:46
Corindus to Showcase CorPath® GRX System at Transcatheter Cardiovascular Therapeutics 2019 Conference
Business Wire · 09/18/2019 10:45
Webull provides a variety of real-time CVRS stock news. You can receive the latest news about CORINDUS VASCULA through multiple platforms. This information may help you make smarter investment decisions.
About CVRS
Corindus Vascular Robotics, Inc. is engaged in robotic-assisted vascular interventions. The Company's CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System it brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. It operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The CorPath System enables the robotic-assisted control of coronary guidewires and balloon/stent devices from the safety of a radiation-protected, ergonomic interventional cockpit. The CorPath System consists of two components: a bedside unit and an interventional cockpit.